The leading Australian CRO for biotechs, Avance Clinical, accepted the prestigious Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award at a global virtual awards ceremony overnight.
Adelaide,
Australia – The leading Australian
CRO for biotechs, Avance
Clinical, accepted the
prestigious Frost & Sullivan 2020
Asia-Pacific CRO Market Leadership Awardat a global virtual awards ceremony overnight.
According to Frost & Sullivan:
“The Frost & Sullivan Best Practices awards have identified and
honored best-in-class companies that have demonstrated excellence in their
respective industries. Award recipients were identified based on in-depth
interviews, analysis, and extensive secondary research conducted by Frost &
Sullivan analysts and companies are typically studied on their revenues, market
share, capabilities, and overall contribution to the industry in order to
identify best practices.”
This is the first Frost & Sullivan award for the company which has
seen rapid growth in the APAC region over the past year.
Avance Clinical CEO Yvonne Lungershausen commended her team of more than
100 clinical trial specialists throughout Australia and New Zealand.
“We have shown, with our repeat
business rate greater than 75%, that our consistent sponsor focussed culture and nimble proactive approach
wins every time. This has been recognised by the research team at Frost & Sullivan and the entire Avance
Clinical team are very proud.”
“Australia, which has successfully managed the COVID-19 crisis, is open
for business for clinical trials. This award further reinforces to the biotech
community that this is an early phase specialist destination where they can
turn around delayed trials.”
“Avance Clinical are experts in facilitating fast study start up with
trials typically approved and initiated in under 6 weeks.”
Avance Clinical is an Australian owned Contract Research Organisation
that has been providing high-quality clinical research services fit for global
regulatory standards to the local and international drug development industry
for 20 years.
Avance specialises in supporting biotech companies with their early
phase clinical trials having conducted over 150 early phase (Phase 1 and 2)
trials in the past 4 years involving treatment of over 8,300 participants
across 95 therapeutic indications.
According to Nidhi Jalali, Analyst Best Practices, Frost & Sullivan:
“Within Asia-Pacific’s highly competitive CRO market, Avance
Clinical stands out as a leader in early phase biotech clinical trials. The
company offers a highly responsive and proactive service for biotechs wanting
rapid and innovative clinical trial solutions, with the highest level of data
compliance.
Avance Clinical is a full service CRO with a 20-year track-record.
The company has grown quickly over the past year doubling staff numbers
and with plans to further expand in the region. Avance Clinical offers a real
size match for biotechs that means better mission understandings and stronger
customer service compared to some of the larger CROs.
Avance’s reputation for high-quality clinical trial outcomes leveraging
its scientific and regulatory expertise has attracted an impressive 74% repeat
business rate, underscoring the company’s position as a market leader.”
In addition to the impressive COVID-19 management in Australia, a key
factor in sponsor demand is the speed, access to high quality sites and attractive
cost of running trials in Australia including:
The Australian Government
financial rebate of up to 43.5%
on clinical trial spend
No IND required for clinical trials
and streamlined regulatory processes
Advanced medical, research and
scientific community, leading investigators and KOLs, and modern medical
facilities
Australia’s reputation for FDA compliant scientific and research
excellence, its advanced healthcare, and the opportunity to access patients in
a less clinical trial competitive environment further reinforces its advantage
as a destination for clinical trials.
The Frost & Sullivan Best
Practices awards have identified and honored best-in-class companies that have
demonstrated excellence in their respective industries. Award recipients were
identified based on in-depth interviews, analysis, and extensive secondary
research conducted by Frost & Sullivan analysts and companies are typically
studied on their revenues, market share, capabilities, and overall contribution
to the industry in order to identify best practices.
For the Market Leadership Award,
Frost & Sullivan analysts independently elucidated the following key
benchmarking criteria:
1. Technology Leverage
2. Customer Purchase Experience
3. Price/Performance Value
4. Growth Strategy Excellence
5. Customer Service Experience
6. Brand Strength
With its strong overall
performance, Avance Clinical Pty Ltd has earned the 2020 Asia-Pacific CRO
Market Leadership Award. We also recognize that your receipt of this award is
the result of many individuals (employees, customers and investors) making
daily choices to believe in the organization and contribute in a meaningful way
to its future.
About Avance Clinical
Australia’s Avance Clinical has
more than 20-years of experience and is now one of Australia’s leading Contract
Research Organisations. Avance Clinical facilitates quality drug development by
aligning people, skills, and expertise in the pursuit of drug development for a
healthier world.
Avance Clinical is committed to
providing high-quality clinical research services with its highly-experienced
team.
The collective pool of knowledge
and experience at Avance Clinical continually grows through the careful
selection of experts who also demonstrate passion in their chosen field.
Avance Clinical offers high
quality services in an established clinical trial ecosystem, that includes
world-class Investigators and Sites able to access specialised patient groups.
Other benefits include:
The Government R&D grant means up to 43.5% rebate on clinical
trial spend
Telehealth pivot during COVID-19 pandemic – speed and continuity
Site Initiation Visit (SIV) and Study Start achieved
in 5 – 6 weeks
No IND required for clinical trials
Full GMP material is not mandated for Phase I clinical trials
Established clinical trial environment with world-class
Investigators and sites
Established healthy subject databases and specialised patient
populations
Five independent Phase 1 facilities across Australia including
hospital-based units for critical care
Major hospitals with world class infrastructures and dedicated
Clinical Trial Units with a long track-record in FDA compliant research
Seasonal studies: Northern hemisphere Sponsors can conduct their
studies year-round by taking advantage of Australia’s counter-flu and
allergy seasons